Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Commentary|Articles|June 15, 2026
From Ovarian to Endometrial Cancer, Experts Spotlight Standout Data From ASCO 2026
Author(s)Caroline Seymour, Ashling Wahner
Fact checked by: Courtney Flaherty, Tracy Ann Politowicz
ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.
Advertisement
Advertisement
OncLive® connected with gynecologic oncology experts at the
Related to this article
PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Advertisement
Advertisement